Abstract Details

Title Treating Mild, Moderate, or Severe Spasticity Matters to People with Multiple Sclerosis - SEEN-MSS Survey

Topic Multiple Sclerosis

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-006

Background Spasticity occurs in up to 80% of those with MS. Evidence suggests that PwMSS experience worsening of multiple concurrent symptoms, which negatively impact other aspects of their lives.

Objective To understand the comprehensive impact of spasticity for people with multiple sclerosis and spasticity (PwMSS) and the importance of treating spasticity, regardless of severity (mild, moderate, or severe).

Design/Methods SEEN-MSS (Symptoms and Emotions Exploration Needed in Multiple Sclerosis Spasticity), a cross-sectional, online survey, was developed in collaboration with three MS advocacy organizations and completed by US-based PwMSS from February-April 2021.

Results The survey was completed by 1,177 adult PwMSS; 78% female, mean age 56.8 years. Participants reported a mean of 16.8 years from MS diagnosis and spasticity symptoms for 11.5 years. In this survey, severity of spasticity was determined utilizing a numeric rating scale score. Mild was a score of 1-3 (n=211), moderate was 4-6 (n=476) and severe was 7-10 (n=468). Spasticity was ranked among the top five most problematic symptoms for 72%. Overall, 70% of participants, of which 40% had mild spasticity, stated that treating spasticity is a top priority. Approximately half of all participants, including 35% of those with mild spasticity, reported that spasticity exacerbated muscle weakness, fatigue, balance problems, and difficulty walking. More than 85% of participants reported spasticity affecting domains of daily living and 69%, 81%, 85%, and 84% of participants with mild spasticity indicated impacts on emotions, sleep, ability to move, and pain, respectively. Overall, 82% of participants, including 67% with mild spasticity, felt that adequately managing their spasticity would make them feel more in control of their MS.

Conclusions This survey highlights that treating spasticity is a top priority for PwMSS, even when symptoms are mild. The results emphasize the importance of proactive communication regarding spasticity and addressing individual needs and treatment goals of PwMSS.

Authors/Disclosures
Scott D. Newsome, DO, FAAN (Johns Hopkins Hospital) PRESENTER	Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from The Stiff Person Syndrome Research Foundation. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.
Ben W. Thrower, MD (Shepherd Center)	Dr. Thrower has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Thrower has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Thrower has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon. Dr. Thrower has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS.
Barry A. Hendin, MD, FAAN (Phoenix Neurological Associates Ltd)	Dr. Hendin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen, Genentech, Genzyme, Novartis ,EMD Serono,Alexion. Dr. Hendin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen., Novartis Genentech, Genzyme, EMD Serono, Alexian. Dr. Hendin has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. EMD Serono Genentech Genzyme Novartis Alexian. Dr. Hendin has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Multiple sclerosis association of America. The institution of Dr. Hendin has received research support from Biogen. Genentech.
Robert Chinnapongse, MD	Dr. Chinnapongse has received personal compensation for serving as an employee of Greenwich Biosciences. Dr. Chinnapongse has stock in Greenwich Biosciences.
Sherry R. Danese (Amgen)	No disclosure on file
Jenifer Patterson, NP (Catalyst)	Ms. Patterson has received personal compensation for serving as an employee of Greenwich Biosciences .